A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.

Martijn J H G Simons Peter M Machielsen Jelle A SpoorendonkTim IgnacioPieter B DrostTim JacobsFelix E deJongh

Published in: Journal of medical economics (2024)

Implementing Oncotype DX testing in this population can prevent unnecessary overtreatment, reducing clinical and economic burden on the patient and Dutch healthcare system.

Keyphrases

positive breast cancer
early stage
case report
high throughput
lymph node
copy number
genome wide
sentinel lymph node
dna methylation
gene expression
radiation therapy
neoadjuvant chemotherapy
locally advanced